Investor Relations
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Defining a new era of oligonucleotides
We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.
Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.
1 st
first to design and bring stereopure and
allele-specific medicines to clinic
3
clinical studies initiated in 2017
5
nucleic acid modalities being advanced with Wave stereopure chemistry
12+
discovery programs